2025-07-23 - Analysis Report
Okay, here's a report summarizing the provided data for Eli Lilly and Co (LLY).

**Report on Eli Lilly and Co (LLY)**

**1. Performance Overview**

*   **Ticker:** LLY
*   **Company Description:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1.1. Returns vs. S&P 500 (VOO)**

*   **LLY Cumulative Return:** 243.78%
*   **VOO Cumulative Return:** 97.07%
*   **Absolute Spread:** 144.8
*   **Relative Spread Position:** 50.8 (This indicates LLY's outperformance relative to VOO is in the middle range of its historical spread.)
*   **Analysis:** LLY has significantly outperformed the S&P 500. The relative spread position suggests that while the outperformance is substantial, it's not at the extreme high end of its historical range.

**1.2. Alpha, Beta Analysis & Other Indicators**

| Year       | CAGR    | MDD    | Alpha    | Beta   | Cap(B) |
|------------|---------|--------|----------|--------|--------|
| 2015-2017  | 10.0%   | 56.3%  | -19.0%   | 0.0    | 75.8   |
| 2016-2018  | 39.0%   | 58.6%  | 21.0%    | -0.1   | 103.9  |
| 2017-2019  | 50.0%   | 58.6%  | 20.0%    | 0.3    | 118.0  |
| 2018-2020  | 52.0%   | 58.6%  | 33.0%    | 0.1    | 151.6  |
| 2019-2021  | 106.0%  | 60.6%  | 57.0%    | 0.2    | 248.0  |
| 2020-2022  | 98.0%   | 64.8%  | 96.0%    | 0.2    | 328.4  |
| 2021-2023  | 133.0%  | 64.8%  | 115.0%   | 0.3    | 523.3  |
| 2022-2024  | 150.0%  | 72.2%  | 124.0%   | 0.2    | 693.0  |
| 2023-2025  | 97.0%   | 76.8%  | 48.0%    | 0.2    | 697.0  |

*   **CAGR:** Compounded Annual Growth Rate (Yearly growth rate) is relatively stable, though showing signs of slowing down, but generally remains very high over the periods shown.
*   **MDD:** Maximum DrawDown is increasing, showing more volatility and less stability.
*   **Alpha:** Alpha has remained high over the periods shown
*   **Beta:** Beta is generally low, showing that it is not moving in sync with the market, implying that it moves in its own direction.

**2. Recent Price Action**

*   **Current Price:** $776.44
*   **Previous Close:** $762.18
*   **Change:** 1.87% (This is a significant jump, indicating a positive short-term price movement)
*   **5-day Moving Average:** 772.326
*   **20-day Moving Average:** 780.8965
*   **60-day Moving Average:** 777.4512
*   **Analysis:** The price is above the 5-day moving average, but below the 20-day and 60-day moving averages.  The recent price surge suggests a potential short-term upward trend, but longer-term trends are still showing downward.

**3. Technical Indicators & Market Risk**

*   **Market Risk Indicator (MRI):** 0.3359 (Low Risk)
*   **RSI:** 50.18 (Neutral - neither overbought nor oversold)
*   **PPO:** -0.29 (Negative, indicating a slight downward trend)
*   **Hybrid Signal:** cash_69%_Sell 69.7% of holdings
*   **Delta_Previous_Relative_Divergence (20-day):** -5.6 (Negative, indicating a short-term decline in relative performance)
*   **Expected Return:** 155.5% (This is a very high projected excess return over the S&P 500 for a long-term investment horizon)
*   **Analysis:**  The Hybrid Signal is suggesting to sell 69.7% of holdings and move to cash. A negative PPO and delta divergence suggest caution, while the MRI indicates low overall market risk.

**4. Recent News & Events**

*   **[2025-07-21]:** Major business developments, regulatory changes, or market events impacting LLY.
*   **[2025-07-22]:** Analyst discussions regarding LLY's performance, industry trends, and global economic factors.
*   **[2025-07-23]:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-19]:** Market experts highlighting both risks and opportunities, advising investors to monitor news.
*   **Analysis:** Recent news suggests that LLY is subject to market-moving events, which may be the reason for the recent volatility.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2024-08-08 | 3.29 | 11.30 B$   |
| 2024-04-30 | 2.49 | 8.77 B$   |
| 2025-05-01 | 2.49 | 8.77 B$   |

*   **Trend:** EPS and Revenue have generally been increasing, with a notable jump in the most recent quarter, and then returning to prior levels. This suggests that LLY has achieved significant revenue increases.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-03-31 | $15.76B   | 17.50%  |
| 2024-12-31 | $14.19B   | 31.07%  |
| 2024-09-30 | $14.24B   | 6.81%   |
| 2024-06-30 | $13.56B   | 21.88%  |
| 2024-03-31 | $12.81B   | 17.51%  |

*   **Analysis:** Both Revenue and Profit Margin have been on an upward trend. This indicates strong financial performance and efficient operations. Equity has also increased, indicating healthy growth. Return on Equity (ROE) has fluctuated.

**7. Overall Assessment**

Eli Lilly and Co (LLY) exhibits very strong performance characteristics:

*   **Outperformance:** LLY has significantly outperformed the S&P 500 over the long term.
*   **Financial Strength:** Revenue, profit margins, and equity are generally growing.
*   **Growth:** CAGR remains very high over the periods shown.

**Considerations:**

*   **Hybrid Signal(Sell):** The hybrid signal is suggesting to sell 69.7% of holdings.
*   **Recent News:** Recent news indicates LLY is sensitive to specific events.
*   **Volatility:** The news and the divergence/PPO indicator suggests the stock may be volatile in the near term.
